Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537382 | 0.86 | L3MBTL1 (0.41) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL1918380 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL1918087 | 0.83 | L3MBTL1 (0.40) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL10241548 | 0.83 | CYP2C9 (0.43) | CYP3A4CYP2C9CYP2C19KCNH2L3MBTL1 | |
| SCHEMBL1918575 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL10240065 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL18809567 | 0.80 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL14217309 | 0.76 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2837514 | 0.75 | ANO1 (0.46) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL3540383 | 0.75 | ANO1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |